Psychotic Disorders and Substance Use Disorders

2020 ◽  
pp. 1341-1355
Author(s):  
Daniele Carretta ◽  
Francesco Bartoli ◽  
Giuseppe Carrà
Keyword(s):  
Substance Use ◽  
Substance Use Disorders ◽  
Psychotic Disorders

Psychotic Disorders and Substance Use Disorders

2014 ◽  
pp. 2013-2034
Author(s):  
Daniele Carretta ◽  
Massimo Clerici ◽  
Francesco Bartoli ◽  
Giuseppe Carrà
Keyword(s):  
Substance Use ◽  
Substance Use Disorders ◽  
Psychotic Disorders

scholarly journals The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review

2019 ◽  
Vol 8 (7) ◽  
pp. 1058 ◽  
Author(s):  
Albert Batalla ◽  
Hella Janssen ◽  
Shiral S. Gangadin ◽  
Matthijs G. Bossong
Keyword(s):  
Substance Use ◽  
Substance Use Disorders ◽  
Psychotic Disorders ◽  
Cannabis Use ◽  
Standardized Measures ◽  
Positive Effects ◽  
Promising Tool ◽  
Potential Biomarker ◽  
Endogenous Cannabinoid ◽  
The Relationship

The endogenous cannabinoid (eCB) system plays an important role in the pathophysiology of both psychotic disorders and substance use disorders (SUDs). The non-psychoactive cannabinoid compound, cannabidiol (CBD) is a highly promising tool in the treatment of both disorders. Here we review human clinical studies that investigated the efficacy of CBD treatment for schizophrenia, substance use disorders, and their comorbidity. In particular, we examined possible profiles of patients who may benefit the most from CBD treatment. CBD, either as monotherapy or added to regular antipsychotic medication, improved symptoms in patients with schizophrenia, with particularly promising effects in the early stages of illness. A potential biomarker is the level of anandamide in blood. CBD and THC mixtures showed positive effects in reducing short-term withdrawal and craving in cannabis use disorders. Studies on schizophrenia and comorbid substance use are lacking. Future studies should focus on the effects of CBD on psychotic disorders in different stages of illness, together with the effects on comorbid substance use. These studies should use standardized measures to assess cannabis use. In addition, future efforts should be taken to study the relationship between the eCB system, GABA/glutamate, and the immune system to reveal the underlying neurobiology of the effects of CBD.

scholarly journals O3.3. COMORBID SUBSTANCE USE DISORDERS ASSOCIATED WITH LIFE EXPECTANCY REDUCTION IN PEOPLE WITH PSYCHOTIC DISORDERS: AN ELECTRONIC CASE REGISTER STUDY

2019 ◽  
Vol 45 (Supplement_2) ◽  
pp. S166-S166
Author(s):  
Rashmi Patel ◽  
Edward Chesney ◽  
Sam Hollandt ◽  
Chi-Kang Chang ◽  
Megan Pritchard ◽  
...  
Keyword(s):  
Substance Use ◽  
Life Expectancy ◽  
Substance Use Disorders ◽  
Psychotic Disorders ◽  
Register Study ◽  
Case Register

Substance use disorders and psychotic disorders in epilepsy: A population-based registry study

2014 ◽  
Vol 108 (8) ◽  
pp. 1435-1443 ◽  
Author(s):  
Inger Johanne Bakken ◽  
Eline Revdal ◽  
Ragnar Nesvåg ◽  
Eiliv Brenner ◽  
Gun Peggy Knudsen ◽  
...  
Keyword(s):  
Substance Use ◽  
Substance Use Disorders ◽  
Psychotic Disorders ◽  
Population Based ◽  
Registry Study ◽  
Population Based Registry

Comparative study of psychiatric comorbidity differences in patients with ADHD and cocaine substance use disorders and patients ADHD and cannabis use disorders

2017 ◽  
Vol 41 (S1) ◽  
pp. S477-S477
Author(s):  
N. Martínez-Luna ◽  
L. Rodriguez-Cintas ◽  
C. Daigre ◽  
L. Grau-Lopez ◽  
R.F. Palma-Alvarez ◽  
...  
Keyword(s):  
Substance Use ◽  
Substance Use Disorders ◽  
Drug Users ◽  
Psychiatric Comorbidity ◽  
Psychotic Disorders ◽  
Neuronal Damage ◽  
Total Sample ◽  
Cocaine Users ◽  
The Difference ◽  
Competing Interest

Substance Use Disorders (SUD) and Attention Deficit Hyperactive Disorder (ADHD) are frequent conditions in out drug treatment centers. There are evidences about the high prevalence of ADHD in SUD patients (20%) compared with just ADHD in general population (1–7.3%). Both disorders and psychiatric comorbidity are important in the diagnosis proceeding. The objective of this study is search the difference in psychiatric comorbidity conditions between patients with ADHD and Cocaine SUD and ADHD and Cannabis SUD. ADHD was present in 158 patients of a total sample in which 46,8% used cocaine, 17.1% cannabis and 36.1% used both. Mood disorders were 26.8% in cocaine users, 21.7% in cannabis and 18.9% in both. Anxiety disorders were 20.3% in cocaine users, 37.5 in cannabis and 13% in both users. Primary psychotic disorders were 2.9% in cocaine users, none in cannabis and 11,1% in both drug users. Personality disorders by cluster were, Cluster A: 11.3% in cocaine group, 36% in cannabis group and 24.5 in cannabis and cocaine group. Cluster B: 33.8% in cocaine group, 44% in cannabis group and 51.9% in cannabis and cocaine group. Cluster C: 9.9% in cocaine group, 28% in cannabis group and 19.2% in cannabis and cocaine group. There could be common pathways of neuronal damage related to psychiatric comorbidity depending of used drug, the differences in comorbidity found in this study could explain a little part of it. It is important to manage SUD-ADHD and other psychiatric comorbidity in order to improve the outcomes of these patients.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Co-occurring Substance Use Disorders

2017 ◽  
Author(s):  
Michael Soule ◽  
Hilary S. Connery
Keyword(s):  
Mental Health ◽  
Substance Use ◽  
Substance Use Disorders ◽  
Psychotic Disorders ◽  
Behavioral Therapy ◽  
Contingency Management ◽  
Integrated Treatment ◽  
Mental Health Clinics ◽  
Medication Assisted Treatment ◽  
Community Mental Health Clinics

Substance use disorders are frequently comorbid with mood, anxiety, and psychotic disorders, and they commonly present in tandem in both primary care and psychiatric settings. Unfortunately, in the past, individuals with co-occurring substance use and mental health disorders would receive treatment in community mental health clinics only after their substance use disorder was “stabilized.” There has been increasing recognition that integrated treatment is necessary for these individuals to fully succeed and achieve recovery. This chapter uses a common presentation to illustrate up-to-date screening and treatment recommendations. Motivational interviewing, contingency management, cognitive–behavioral therapy, and medication-assisted treatment are explored. A discussion of the continuum of community-based services and systems challenges follows.

Neuropsychological Profile of Various Neurological and Psychiatric Conditions

2020 ◽  
pp. 149-197
Author(s):  
Ramprasad Santhanakrishnan K.
Keyword(s):  
Substance Use ◽  
Mental Disorders ◽  
Personality Disorders ◽  
Mood Disorders ◽  
Substance Use Disorders ◽  
Psychotic Disorders ◽  
Sexual Disorders ◽  
Childhood Disorders ◽  
Neuropsychological Profile ◽  
Psychiatric Conditions

In the current chapter, the neuropsychological profile of various neurological and psychiatric conditions is focused on, including two major divisions (i.e., dementia—cortical and sub-cortical—and major mental disorders—substance use disorders, mood disorders, anxiety disorders, psychotic disorders, sleep disorders, childhood disorders, personality disorders, and sexual disorders). Both divisions have sub-classifications that include introduction, etiopathogenesis, epidemiology, clinical features, evaluation, treatment, and psychosocial aspects.

scholarly journals Meta-Analysis on the Effect of Contingency Management for Patients with Both Psychotic Disorders and Substance Use Disorders

2021 ◽  
Vol 10 (4) ◽  
pp. 616
Author(s):  
Marianne Destoop ◽  
Lise Docx ◽  
Manuel Morrens ◽  
Geert Dom
Keyword(s):  
Substance Use ◽  
Substance Use Disorders ◽  
Psychotic Disorders ◽  
Meta Analysis ◽  
Contingency Management ◽  
Potential Effect ◽  
Clinical Population ◽  
Clinical Implementation ◽  
Effective Interventions ◽  
Evidence Based Treatments

Background: Substance use disorders (SUD) are highly prevalent among psychotic patients and are associated with poorer clinical and functional outcomes. Effective interventions for this clinical population are scarce and challenging. Contingency management (CM) is one of the most evidence-based treatments for SUD’s, however, a meta-analysis of the effect of CM in patients with a dual diagnosis of psychotic disorder and SUD has not been performed. Methods: We searched PubMed and PsycINFO databases up to December 2020. Results: Five controlled trials involving 892 patients were included. CM is effective on abstinence rates, measured by the number of self-reported days of using after intervention (95% CI −0.98 to −0.06) and by the number of negative breath or urine samples after intervention (OR 2.13; 95% CI 0.97 to 4.69) and follow-up (OR 1.47; 95% CI 1.04 to 2.08). Conclusions: Our meta-analysis shows a potential effect of CM on abstinence for patients with SUD and (severe) psychotic disorders, although the number of studies is limited. Additional longitudinal studies are needed to confirm the sustained effectivity of CM and give support for a larger clinical implementation of CM within services targeting these vulnerable co-morbid patients.

Sign in / Sign up

Export Citation Format

Share Document